CClinicalTrials.gg
Sign In
RecruitingNCT05672706Updated Jan 5, 2023

A Study of Pressure Waveform Analysis in Coronary Artery-II

An observational study in Ischemic Heart Disease, sponsored by National Taiwan University Hospital Hsin-Chu Branch. Recruiting at 1 site in Taiwan. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-01-05.

Sponsored by National Taiwan University Hospital Hsin-Chu Branch · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
21 Years and older
Sex
All
01

Study summary

The goal of this observational study is to test the feasibility of intracoronary adenosine administration during coronary flow reserve(CFR) and index of microcirculatory resistance(IMR) assessment in a population with angina. The main questions it aims to answer are:

  • Repeatability of CFR and IMR assessment while hyperemia with intracoronary adenosine was administered.
  • Evaluate the correlation of the intrinsic signal of coronary waveform versus physiologic ischemia, while defined by fractional flow reserve(FFR) and CFR respectively.
  • The predictive value of FFR, CFR, and IMR on major adverse cardiovascular outcomes in 3 years Participants will undergo FFR, CFR, and IMR assessments in the catheterization laboratory of the National Taiwan University Hospital Hsin-Chu Branch, then clinical events follow up for 3 years.
02

Conditions studied

  • Ischemic Heart Disease
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's planned enrollment of 30 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

National Taiwan University Hospital Hsin-Chu Branch is the lead sponsor of 35 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with angina and undergo invasive coronary angiography

Inclusion criteria

  • Participants with angina

Exclusion criteria

Exclusion Criteria:

  • Severe valvular heart disease
  • History of asthma
  • Heart rate less than 50 beats per minute
  • systolic blood pressure less than 90 mmHg
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • CFR and IMR group

    Procedure: CFR and IMR group

Interventions

  • ProcedureCFR and IMR group

    Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement

06

What researchers measure

Primary outcomes

  1. Repeatability of CFR and IMR value

    To compare the difference of individual value, while repeat the measurement within 1 minutes

    Time frame: 10 minutes

Secondary outcomes

  1. Major adverse cardiovascular outcomes

    Including death, myocardial infarction, stroke and heart failure

    Time frame: 3 year

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital Hsin-Chu branch
    Hsinchu, 300, Taiwan
    • Chien-Boon Jong, MD · Contact · jgboon0407@gmail.com · 035322140
    • Chien-Boon Jong, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05672706
Lead sponsor
National Taiwan University Hospital Hsin-Chu Branch
Responsible party
Sponsor
First posted
Jan 5, 2023
Start date
Jan 4, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 5, 2023

Study contacts

Chien-Boon Jong, MD
Contact
jgboon0407@gmail.com
035322140 ext. 2010

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Diseases→

Other studies from this sponsor

National Taiwan University Hospital Hsin-Chu Branch

Start the discussion